19.75
+0.10%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Silence Therapeutics
From its filings with the US Securities and Exchange Commission
Silence Therapeutics is based in London and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker SLN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $559,000 and a net loss of $88.6m. At that date it held total assets of $131.4m and shareholders' equity of $62.3m.
We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Our siRNA molecules are designed to harness the body’s natural mechanism of RNAi by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. By degrading the message that encodes the disease-associated protein, the production of that protein is reduced and its level of activity is lowered. In the field of RNAi therapeutics, this reduction of disease-associated protein production and activity is referred to as “gene silencing.” Our proprietary mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform consists of siRNA product candidates designed to precisely target and ‘silence’ specific disease-associated genes in the liver. Using our mRNAi GOLD platform, we have generated siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Sept 2020
- Employees
- 21
- Website
- silence-therapeutics.com ↗
- Head office
- 12 HAMMERSMITH GROVE, LONDON, W6 7AP
- Incorporated in
- X0
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Silence Therapeutics develops Divesiran for polycythemia vera treatment in hematology.
- The company focuses on siRNA molecules for rare diseases segment.
- Zerlasiran targets cardiovascular disease associated with elevated lipoprotein(a) levels.
Weaknesses
- The firm has only 21 employees in the Health Care sector.
- Divesiran remains in Phase 2 development for polycythemia vera patients.
- SLN548 is still under development for complement-mediated renal diseases.
Opportunities
- SLN312 offers potential treatment for patients with dyslipidemia conditions.
- SLN365 addresses the market need for hypercholesterolemia therapies.
- SLN098 targets the growing obesity treatment segment globally.
Threats
- Phase 2 clinical trials for Divesiran may face regulatory hurdles.
- Competitors in hematology may develop superior siRNA therapies.
- Rare diseases segment faces limited patient population sizes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.